Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880998 | 0.87 | SLC6A2 (0.39) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6284637 | 0.80 | TAAR1 (0.43) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3019820 | 0.79 | — | — | |
| SCHEMBL6529491 | 0.79 | TAAR1 (0.48) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28084161 | 0.79 | TAAR1 (0.39) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5770282 | 0.79 | TAAR1 (0.42) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27911335 | 0.79 | TAAR1 (0.54) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL250854 | 0.77 | TAAR1 (0.53) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4446755 | 0.77 | TAAR1 (0.53) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15284196 | 0.77 | TAAR1 (0.47) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017011518-A1 | PROTEIN ACYL TRANSFERASE INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| EP-1778685-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| EP-1771448-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1519726-B1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1749529-A1 | Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases | SCHWARZ PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1733727-A1 | Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders | SCHWARZ PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006050976-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006015737-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-6982260-B1 | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes | WARNER-LAMBERT COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1519726-A1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SCHWARZ PHARMA AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004004729-A1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SCHWARZ PHARMA AG (DE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1235815-A1 | QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASE ENZYMES | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001038315-A1 | QUINAZOLINES AND THEIR USE FOR INHIBITING CYCLIN-DEPENDENT KINASE ENZYMES | WARNER-LAMBERT COMPANY (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | TAAR1 73/4885CYP2D6 360/4885SLC6A2 30/4885 |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | TAAR1 176/4885CYP2D6 249/4885SLC6A2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.